Long-term outcomes of durvalumab after chemoradiotherapy in locally advanced non-small cell lung cancer in Russia

Introduction. The results of the PACIFIC trial have changed the standards of care for the patients with unresectable stage III nonsmall cell lung cancer (NSCLC). However, many patients in our clinical practice do not meet the inclusion criteria of PACIFIC trial.

Aim. To evaluate the long-term outcomes for this approach in real clinical practice in Russia.

Materials and мethods. This real-world observational retrospective multicenter study analyzed clinical outcomes in 100 patients with unresectable stage III NSCLC after concurrent or sequential chemoradiotherapy (CRT). The overall survival (OS) and progression-free survival (PFS) were evaluated by the Kaplan-Meyer method. Multivariate subgroups analysis was performed as well. The median follow-up time was 22.7 months.

Results. There were 96% patients with ECOG/WHO performance status 0 or 1 in our study. Most of the patients were treated by sequential CRT (76%). Median time of durvalumab start from the end of CRT was 34 days. Patients received durvalumab for a median 10 months. The estimated median progression-free survival (PFS) and overall survival (OS) were 14.3 months (11.8–16.7, 95% CI) and 29 months (18.7–39.2, 95% CI), respectively. The estimated 1-year and 2-year rates for OS and for PFS were 90.4%, 62.8% and 59.1%, 35%, respectively. In multivariate analysis, a smoking history (HR = 0.21 (0.10–0.45; 95% CI) and concurrent CRT (HR = 0.3 (0.12–0.74; 95%CI) were associated with better PFS. The smoking history was significantly associated with a better OS (HR = 0.29 (0.10–0.76; 95% CI)) as well.

Conclusions. There is a difference between the real-world outcomes for patients with unresectable stage III NSCLC in Russia and the PACIFIC trial. Sequential CRT is the most frequent treatment option for locally advanced unresectable NSCLC in Russia, and estimated OS and PFS are shorter than in the PACIFIC clinical trial. A paradigm shift in chemoradiotherapy to the concurrent and personalized approach could change the current situation.

1. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022. 239 с.

2. Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, Rodríguez-Martínez Á, Giraldo-Osorio A, Varela-Lema L et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506–518. https://doi.org/10.21037/tlcr.2020.03.40.

3. Provencio M, Carcereny E, Rodríguez-Abreu D, López-Castro R, Guirado M, Camps C et al. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Transl Lung Cancer Res. 2019;8(4):461–475. https://doi.org/10.21037/tlcr.2019.08.05.

4. Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax. 2013;68(6):551–564. https://doi.org/10.1136/thoraxjnl-2012-202297.

5. Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F et al. Stage III NonSmall-Cell Lung Cancer: An Overview of Treatment Options. Curr Oncol. 2023;30(3):3160–3175. https://doi.org/10.3390/curroncol30030239.

6. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–2190. https://doi.org/10.1200/JCO.2009.26.2543.

7. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–1929. https://doi.org/10.1056/NEJMoa1709937.

8. Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860–867. https://doi.org/10.1016/j.jtho.2020.12.015.

9. Spigel D, Faivre-Finn C, Gray J, Vicente D, Planchard D, Paz-Ares L et al. Fiveyear survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. J Clin Oncol. 2021;39(15):8511–8511. https://doi.org/10.1200/JCO.2021.39.15_suppl.8511.

10. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F et al. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2023;18(2):181–193. https://doi.org/10.1016/j.jtho.2022.10.003.

11. Лактионов КК, Артамонова ЕВ, Борисова ТН, Бредер ВВ, Бычков ЮМ, Владимирова ЛЮ и др. Злокачественное новообразование бронхов и легкого: клинические рекомендации. М.; 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/30_3.

12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026.

13. Park CK, Oh HJ, Kim YC, Kim YH, Ahn SJ, Jeong WG et al. Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR. J Thorac Oncol. 2023;18(8):1042–1054. https://doi.org/10.1016/j.jtho.2023.04.008.

14. Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N et al. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. J Radiat Res. 2023;64(1):142–153. https://doi.org/10.1093/jrr/rrac057.

15. Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer. 2020;150:114–122. https://doi.org/10.1016/j.lungcan.2020.10.006.

16. Park JE, Hong KS, Choi SH, Lee SY, Shin KC, Jang JG et al. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study. Clin Lung Cancer. 2024;25(4):354–364. https://doi.org/10.1016/j.cllc.2024.02.006.

17. Waterhouse D, Yong C, Frankart A, Brannman L, Mulrooney T, Robert N et al. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting. Future Oncol. 2023;19(28):1905–1916. https://doi.org/10.2217/fon-2023-0117.

18. Vrankar M, Stanic K, Jelercic S, Ciric E, Vodusek AL, But-Hadzic J. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience. Radiol Oncol. 2021;55(4):482–490. https://doi.org/10.2478/raon-2021-0044.

19. Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D’Angelo E et al. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Front Oncol. 2021;11:744956. https://doi.org/10.3389/fonc.2021.744956.

20. Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M et al. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clin Transl Oncol. 2024;26(7):1779–1789. https://doi.org/10.1007/s12094-024-03404-9.

21. Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N et al., Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022;17(12):1415–1427. https://doi.org/10.1016/j.jtho.2022.07.1148.

22. Zhao B, Li H, Wu J, Ma W. Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2023;18(1):1–2. https://doi.org/10.1016/j.jtho.2022.09.002.